Skip to main content
Top
Published in: BMC Neurology 1/2015

Open Access 01-12-2015 | Research article

Exploratory screening for Fabry’s disease in young adults with cerebrovascular disorders in northern Sardinia

Authors: Laura Fancellu, Walter Borsini, Ilaria Romani, Angelo Pirisi, Giovanni Andrea Deiana, Elia Sechi, Pietro Emiliano Doneddu, Anna Laura Rassu, Rita Demurtas, Anna Scarabotto, Pamela Cassini, Eloisa Arbustini, GianPietro Sechi

Published in: BMC Neurology | Issue 1/2015

Login to get access

Abstract

Background

The etiologic determinants of stroke in young adults remain a diagnostic challenge in up to one-fourth of cases. Increasing evidences led to consider Fabry’s disease (FD) as a possible cause to check up. We aimed at evaluating the prevalence of unrecognized FD in a cohort of patients with juvenile stroke in northern Sardinia.

Methods

For this study, we enrolled 178 patients consecutively admitted to our Neurological Ward for ischemic stroke, transient ischemic attack, intracerebral haemorrhage, neuroradiological evidence of silent infarcts, or white matter lesions possibly related to cerebral vasculopathy at brain MRI, and cerebral venous thrombosis. The qualifying events have to occur between 18 and 55 years of age.

Results

We identified two patients with an α-galactosidase A gene variant, with a prevalence of 0.9 %. According to recent diagnostic criteria, one patient, included for the occurrence of multiple white matter lesions at brain MRI, had a diagnosis of definite FD, the other, included for ischemic stroke, had a diagnosis of uncertain FD.

Conclusions

Our study places in a middle position among studies that found a prevalence of FD up to 4 % and others that did not find any FD patients. Our findings confirm that FD should be considered in the differential diagnosis of patients with juvenile stroke, particularly those with a personal or familial history positive for cerebrovascular events, or evidence of combined cardiologic and/or renal impairment. All types of cerebrovascular disorders should be screened for FD, including patients with white matter lesions possibly related to cerebral vasculopathy at brain MRI.
Literature
1.
go back to reference Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and Stroke statistics-2011 update: a report from the American Heart association. Circulation. 2011;123:e18–e209.PubMedCentralCrossRefPubMed Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and Stroke statistics-2011 update: a report from the American Heart association. Circulation. 2011;123:e18–e209.PubMedCentralCrossRefPubMed
2.
go back to reference Lackland DT, Roccella EJ, Deutsch AF, Fornage M, George MG, Howard G, et al. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke. 2014;45:315–53.CrossRefPubMed Lackland DT, Roccella EJ, Deutsch AF, Fornage M, George MG, Howard G, et al. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke. 2014;45:315–53.CrossRefPubMed
3.
go back to reference Marini C, Totaro R, De Santis F, Ciancarelli I, Baldassarre M, Carolei A. Stroke in young adults in the community-Based L’Aquila registry: incidence and prognosis. Stroke. 2001;32:52–6.CrossRefPubMed Marini C, Totaro R, De Santis F, Ciancarelli I, Baldassarre M, Carolei A. Stroke in young adults in the community-Based L’Aquila registry: incidence and prognosis. Stroke. 2001;32:52–6.CrossRefPubMed
4.
go back to reference Ferro JM, Massaro AR, Mas JL. Aetiological diagnosis of ischaemic stroke in young adults. Lancet Neurol. 2010;9:1085–96.CrossRefPubMed Ferro JM, Massaro AR, Mas JL. Aetiological diagnosis of ischaemic stroke in young adults. Lancet Neurol. 2010;9:1085–96.CrossRefPubMed
7.
go back to reference Fellgiebel A, Müller MJ, Ginsberg L. CNS manifestations of Fabry’s disease. Lancet Neurol. 2006;5:791–5.CrossRefPubMed Fellgiebel A, Müller MJ, Ginsberg L. CNS manifestations of Fabry’s disease. Lancet Neurol. 2006;5:791–5.CrossRefPubMed
8.
go back to reference Mehta A, Beck M, Eyskens F, Feliciani C, Kantola I, Ramaswami U, et al. Fabry disease: a review of current management strategies. QJM. 2010;103:641–59.CrossRefPubMed Mehta A, Beck M, Eyskens F, Feliciani C, Kantola I, Ramaswami U, et al. Fabry disease: a review of current management strategies. QJM. 2010;103:641–59.CrossRefPubMed
9.
go back to reference Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry registry. Stroke. 2009;40:788–94.CrossRefPubMed Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry registry. Stroke. 2009;40:788–94.CrossRefPubMed
10.
go back to reference Biegstraaten M, Arngrimsson R, Barbey F, Boks L, Cecchi F, Deegan PB, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10:36.PubMedCentralCrossRefPubMed Biegstraaten M, Arngrimsson R, Barbey F, Boks L, Cecchi F, Deegan PB, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10:36.PubMedCentralCrossRefPubMed
11.
go back to reference Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ, Hollak CE. Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet. 2010;47:217–22.CrossRefPubMed Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ, Hollak CE. Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet. 2010;47:217–22.CrossRefPubMed
12.
go back to reference Rolfs A, Bottcher T, Zschiesche M, Morris P, Winchester B, Bauer P, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005;366:1794–6.CrossRefPubMed Rolfs A, Bottcher T, Zschiesche M, Morris P, Winchester B, Bauer P, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005;366:1794–6.CrossRefPubMed
13.
go back to reference Brouns R, Sheorajpanday R, Braxel E, Eyskens F, Baker R, Hughes D, et al. Middelheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke. Clin Neurol Neurosurg. 2007;109:479–84.CrossRefPubMed Brouns R, Sheorajpanday R, Braxel E, Eyskens F, Baker R, Hughes D, et al. Middelheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke. Clin Neurol Neurosurg. 2007;109:479–84.CrossRefPubMed
14.
go back to reference Adams Jr HP, Bendixen BH, Kappelle LJ, Biller J, Love BB. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35–41.CrossRefPubMed Adams Jr HP, Bendixen BH, Kappelle LJ, Biller J, Love BB. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35–41.CrossRefPubMed
15.
go back to reference The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) lnvestigators. Low Molecular Weight Heparinoid, QRG 10172 (Danaparoìd), and outcome After Acute Ischemic Stroke. JAMA. 1998;279:1265–72.CrossRef The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) lnvestigators. Low Molecular Weight Heparinoid, QRG 10172 (Danaparoìd), and outcome After Acute Ischemic Stroke. JAMA. 1998;279:1265–72.CrossRef
16.
go back to reference Kidwell CS, Warach S. Acute ischemic cerebrovascular syndrome: diagnostic criteria. Stroke. 2003;34:2995–8.CrossRefPubMed Kidwell CS, Warach S. Acute ischemic cerebrovascular syndrome: diagnostic criteria. Stroke. 2003;34:2995–8.CrossRefPubMed
17.
go back to reference Morgenstern LB, Hemphill 3rd JC, Anderson C, Becker K, Broderick JP, Connolly Jr ES, et al. Guidelines for the Management of spontaneous intracerebral haemorrhage :a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41:2108–29.PubMedCentralCrossRefPubMed Morgenstern LB, Hemphill 3rd JC, Anderson C, Becker K, Broderick JP, Connolly Jr ES, et al. Guidelines for the Management of spontaneous intracerebral haemorrhage :a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41:2108–29.PubMedCentralCrossRefPubMed
18.
go back to reference Siket MS, Edlow JA. Transient ischemic attack: reviewing the evolution of the definition, diagnosis, risk stratification, and management for the emergency physician. Emerg Med Clin North Am. 2012;30:745–70.CrossRefPubMed Siket MS, Edlow JA. Transient ischemic attack: reviewing the evolution of the definition, diagnosis, risk stratification, and management for the emergency physician. Emerg Med Clin North Am. 2012;30:745–70.CrossRefPubMed
19.
go back to reference Chen Y, Wang A, Tang J, Wei D, Li P, Chen K, et al. Association of white matter integrity and cognitive functions in patients with subcortical silent lacunar infarcts. Stroke 2015; 46: 1123-6. Chen Y, Wang A, Tang J, Wei D, Li P, Chen K, et al. Association of white matter integrity and cognitive functions in patients with subcortical silent lacunar infarcts. Stroke 2015; 46: 1123-6.
22.
go back to reference Van der Tol L, Cassiman D, Houge G, Janssen MC, Lachmann RH, Linthorst GF, et al. Uncertain diagnosis of Fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up. JIMD Rep. 2014;17:83–90.PubMedCentralCrossRefPubMed Van der Tol L, Cassiman D, Houge G, Janssen MC, Lachmann RH, Linthorst GF, et al. Uncertain diagnosis of Fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up. JIMD Rep. 2014;17:83–90.PubMedCentralCrossRefPubMed
23.
go back to reference Smid BE, van der Tol L, Cecchi F, Elliott PM, Hughes DA, Linthorst GE, et al. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int J Cardiol. 2014;177:400–8.CrossRefPubMed Smid BE, van der Tol L, Cecchi F, Elliott PM, Hughes DA, Linthorst GE, et al. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int J Cardiol. 2014;177:400–8.CrossRefPubMed
24.
go back to reference Fancellu L, Deiana GA, Sechi GP. Teaching neuroimages: Neuroimaging leads to recognition of previously undiagnosed Fabry disease. Neurology. 2010;75:e28.CrossRefPubMed Fancellu L, Deiana GA, Sechi GP. Teaching neuroimages: Neuroimaging leads to recognition of previously undiagnosed Fabry disease. Neurology. 2010;75:e28.CrossRefPubMed
26.
go back to reference Mitsias P, Levine SR. Cerebrovascular complications of Fabry’s disease. Ann Neurol. 1996;40:8–17.CrossRefPubMed Mitsias P, Levine SR. Cerebrovascular complications of Fabry’s disease. Ann Neurol. 1996;40:8–17.CrossRefPubMed
27.
go back to reference Wozniak MA, Kittner SJ, Tuhrim S, Cole JW, Stern B, Dobbins M, et al. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke. 2010;41:78–81.PubMedCentralCrossRefPubMed Wozniak MA, Kittner SJ, Tuhrim S, Cole JW, Stern B, Dobbins M, et al. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke. 2010;41:78–81.PubMedCentralCrossRefPubMed
28.
go back to reference Sarikaya H, Yilmaz M, Michael N, Miserez AR, Steinmann B, Baumgartner RW. Zurich Fabry study – prevalence of Fabry disease in young patients with first cryptogenic ischaemic stroke or TIA. Eur J Neurol. 2012;19:1421–6.CrossRefPubMed Sarikaya H, Yilmaz M, Michael N, Miserez AR, Steinmann B, Baumgartner RW. Zurich Fabry study – prevalence of Fabry disease in young patients with first cryptogenic ischaemic stroke or TIA. Eur J Neurol. 2012;19:1421–6.CrossRefPubMed
29.
go back to reference Saposnik G, Lanthier S, Mamdani M, Thorpe KE, Melo M, Pope K, et al. Fabry’s disease: a prospective multicenter cohort study in young adults with cryptogenic stroke. Int J Stroke. 2012;7:265–73.PubMed Saposnik G, Lanthier S, Mamdani M, Thorpe KE, Melo M, Pope K, et al. Fabry’s disease: a prospective multicenter cohort study in young adults with cryptogenic stroke. Int J Stroke. 2012;7:265–73.PubMed
30.
go back to reference Dubuc V, Moore DF, Gioia LC, Saposnik G, Selchen D, Lanthier S. Prevalence of Fabry Disease in Young Patients with Cryptogenic Ischemic Stroke. J Stroke Cerebrovasc Dis. 2013;22:1288-92. Dubuc V, Moore DF, Gioia LC, Saposnik G, Selchen D, Lanthier S. Prevalence of Fabry Disease in Young Patients with Cryptogenic Ischemic Stroke. J Stroke Cerebrovasc Dis. 2013;22:1288-92.
31.
go back to reference Marquardt L, Baker R, Segal H, Burgess AI, Poole D, Hughes DA, et al. Fabry disease in unselected patients with TIA or stroke: population-based study. Eur J Neurol. 2012;19:1427–32.CrossRefPubMed Marquardt L, Baker R, Segal H, Burgess AI, Poole D, Hughes DA, et al. Fabry disease in unselected patients with TIA or stroke: population-based study. Eur J Neurol. 2012;19:1427–32.CrossRefPubMed
32.
go back to reference Shi Q, Chen J, Pongmoragot J, Lanthier S, Saposnik G. Prevalence of Fabry Disease in Stroke Patients-A Systematic Review and Meta-analysis. J Stroke Cerebrovasc Dis. 2014;23:985–92.CrossRefPubMed Shi Q, Chen J, Pongmoragot J, Lanthier S, Saposnik G. Prevalence of Fabry Disease in Stroke Patients-A Systematic Review and Meta-analysis. J Stroke Cerebrovasc Dis. 2014;23:985–92.CrossRefPubMed
33.
go back to reference Baptista MV, Ferreira S, Pinho-E-Melo T, Carvalho M, Cruz VT, Carmona C, et al. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study–screening genetic conditions in Portuguese young stroke patients. Stroke. 2010;41:431–6.CrossRefPubMed Baptista MV, Ferreira S, Pinho-E-Melo T, Carvalho M, Cruz VT, Carmona C, et al. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study–screening genetic conditions in Portuguese young stroke patients. Stroke. 2010;41:431–6.CrossRefPubMed
34.
go back to reference Brouns R, Thijs V, Eyskens F, Van den Broeck M, Belachew S, Van Broeckhoven C, et al. Belgian Fabry study:prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease. Stroke. 2010;41:863–8.CrossRefPubMed Brouns R, Thijs V, Eyskens F, Van den Broeck M, Belachew S, Van Broeckhoven C, et al. Belgian Fabry study:prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease. Stroke. 2010;41:863–8.CrossRefPubMed
35.
go back to reference Rolfs A, Fazekas F, Grittner U, Dichgans M, Martus P, Holzhausen M, et al. Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study. Stroke. 2013;44:340–9.CrossRefPubMed Rolfs A, Fazekas F, Grittner U, Dichgans M, Martus P, Holzhausen M, et al. Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study. Stroke. 2013;44:340–9.CrossRefPubMed
36.
go back to reference Froissart R, Guffon N, Vanier MT, Desnik RJ, Maire I. Fabry disease: D313Y is an alpha galactosidase A sequence variant that cause pseudodeficient activity in plasma. Mol Genet Metab. 2003;80:307–14.CrossRefPubMed Froissart R, Guffon N, Vanier MT, Desnik RJ, Maire I. Fabry disease: D313Y is an alpha galactosidase A sequence variant that cause pseudodeficient activity in plasma. Mol Genet Metab. 2003;80:307–14.CrossRefPubMed
37.
go back to reference Lenders M, Duning T, Schelleckes M, Schmitz B, Stander S, Rolfs A, et al. Multifocal White matter lesions Associated with the D313Y mutation of the alfa-galactosidase A gene. PLoS One. 2013;8:e55565.PubMedCentralCrossRefPubMed Lenders M, Duning T, Schelleckes M, Schmitz B, Stander S, Rolfs A, et al. Multifocal White matter lesions Associated with the D313Y mutation of the alfa-galactosidase A gene. PLoS One. 2013;8:e55565.PubMedCentralCrossRefPubMed
38.
go back to reference Gaspar P, Herrera J, Rodrigues D, Cerezo S, Delgado R, Andrade CF, et al. Frequency of Fabry disease in male and female haemodialysis patients in Spain. BMC Med Genet. 2010;11:19.PubMedCentralCrossRefPubMed Gaspar P, Herrera J, Rodrigues D, Cerezo S, Delgado R, Andrade CF, et al. Frequency of Fabry disease in male and female haemodialysis patients in Spain. BMC Med Genet. 2010;11:19.PubMedCentralCrossRefPubMed
39.
go back to reference Putaala J, Kurkinen M, Tarvos V, Salonen O, Kaste M, Tatlisumak T. Silent brain infarcts and leukoaraiosis in young adults with first-ever ischemic stroke. Neurology. 2009;72:1823–9.CrossRefPubMed Putaala J, Kurkinen M, Tarvos V, Salonen O, Kaste M, Tatlisumak T. Silent brain infarcts and leukoaraiosis in young adults with first-ever ischemic stroke. Neurology. 2009;72:1823–9.CrossRefPubMed
40.
go back to reference Vermeer SE, Longstreth Jr WT, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol. 2007;6:611–9.CrossRefPubMed Vermeer SE, Longstreth Jr WT, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol. 2007;6:611–9.CrossRefPubMed
41.
go back to reference Das RR, Seshadri S, Beiser AS, Kelly-Hayes M, Au R, Himali JJ, et al. Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study. Stroke. 2008;39:2929–35.PubMedCentralCrossRefPubMed Das RR, Seshadri S, Beiser AS, Kelly-Hayes M, Au R, Himali JJ, et al. Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study. Stroke. 2008;39:2929–35.PubMedCentralCrossRefPubMed
42.
go back to reference Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993;43:1683–9.CrossRefPubMed Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993;43:1683–9.CrossRefPubMed
43.
go back to reference Fellgiebel A, Muller MJ, Mazanek M, Baron K, Beck M, Stoeter P. White matter lesion severity in male and female patients with Fabry disease. Neurology. 2005;65:600–2.CrossRefPubMed Fellgiebel A, Muller MJ, Mazanek M, Baron K, Beck M, Stoeter P. White matter lesion severity in male and female patients with Fabry disease. Neurology. 2005;65:600–2.CrossRefPubMed
Metadata
Title
Exploratory screening for Fabry’s disease in young adults with cerebrovascular disorders in northern Sardinia
Authors
Laura Fancellu
Walter Borsini
Ilaria Romani
Angelo Pirisi
Giovanni Andrea Deiana
Elia Sechi
Pietro Emiliano Doneddu
Anna Laura Rassu
Rita Demurtas
Anna Scarabotto
Pamela Cassini
Eloisa Arbustini
GianPietro Sechi
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2015
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-015-0513-z

Other articles of this Issue 1/2015

BMC Neurology 1/2015 Go to the issue